Eli Lilly expanded Gate deal. Eli Lilly stock fell 4.08 percent

Published on 10/08/2026 at 16:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Foundayo cut diabetes risk 57.00 percent in ATTAIN-1. Eli Lilly stock costs EUR 1016.90 on October 8, 2026, down 4.08 percent from EUR 1060.10.

Key points in brief

Eli Lilly expanded its Gate Bioscience collaboration to target difficult-to-drug proteins in a deal worth up to USD 870.0 million.
Foundayo data showed a modeled 57.00 percent reduction in predicted 10-year diabetes risk versus placebo at 72 weeks.
Eli Lilly stock was trading at EUR 1016.90 at Lang & Schwarz on October 8, 2026, down 4.08 percent from EUR 1060.10.
The next earnings call is scheduled for October 29, 2026, at 10:00 a.m. EDT.

Flatlay mit Aktienzertifikat, ISIN-Karte, Insulinpen, Tabletten und Stethoskop auf Holztisch — Flatlay mit Aktienzertifikat und ISIN-Karte zeigt Eli Lilly and Company, ISIN US5324571083, neben medizinischen Utensilien, Illustration mit AI erstellt.

Eli Lilly expanded its Gate Bioscience collaboration on October 5, 2026, in a deal with potential milestone payments exceeding USD 870.0 million, while Eli Lilly stock fell 4.08 percent to EUR 1016.90 at Lang & Schwarz on October 8, 2026. The October 5 agreement adds one target and an option for a second target, according to Yahoo Finance.

Three pipeline milestones carry figures

On September 15, 2026, Lilly said Foundayo data would be presented at the European Association for the Study of Diabetes meeting, including a 16.00 percent lower risk of major adverse cardiovascular events in one analysis, according to Eli Lilly and Company. On October 1, 2026, the company reported that Foundayo 17.2 mg was associated with a modeled 57.00 percent reduction in predicted 10-year type 2 diabetes risk versus placebo at 72 weeks, according to Eli Lilly and Company. The October 5 Gate agreement then added a commercial development milestone with potential value above USD 870.0 million, according to Yahoo Finance.

What does the pipeline mean for sales?

The oncology portfolio generated USD 4.84 billion in revenue in the first half of 2026, up 11.00 percent from the prior-year period, according to Zacks. That comparison matters because growth from Jaypirca, Retevmo and Inluriyo is being assessed alongside slower sales from mature oncology products, giving Lilly a second growth track beyond its established GLP-1 medicines.

Next earnings date is October 29

Lilly's next earnings release is scheduled for October 29, 2026, with the company calendar listing a third-quarter 2026 earnings call at 10:00 a.m. EDT, according to Eli Lilly and Company. Zacks lists consensus adjusted earnings per share of USD 9.83 for the quarter ending September 2026, according to Zacks.

Stock drops below EUR 1,020

Eli Lilly stock was trading at EUR 1016.90 at Lang & Schwarz on October 8, 2026 at 4:37 p.m. CEST, down 4.08 percent versus the Lang & Schwarz prior close of EUR 1060.10 on October 7, 2026. The primary exchange is the NYSE, where the finance quote showed USD 1,144.48 at 10:46 a.m. ET on October 8, 2026; the 52-week range was USD 783.85 to USD 1,292.65.

Market context: Market report S&P 500.

The further course of trading is shown by the continuously updated real-time quote of Eli Lilly stock.